India Veterinary Analgesics Anti Inflammatory Market Size, Share, Growth, and Industry Analysis, By Drug Class (NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)CarprofenMeloxicamFirocoxibDeracoxibRobenacoxibKetoprofenFlunixin MeglumineTolfenamic Acid, OpioidsBuprenorphineButorphanolFentanyl (patches), Adjunctive AnalgesicsGabapentinAmantadineTramadol), By Animal Type (Companion AnimalsDogsCatsOthers (rabbits, ferrets, etc.), Livestock AnimalsCattleSwinePoultrySheep and GoatsHorses) and Forecast, 2026-2034

India Veterinary Analgesics Anti-Inflammatory Market Trends

Shift Toward Multimodal and Companion-Animal Pain Management

Veterinary pain protocols are increasingly combining anti-inflammatory therapy with adjunctive agents and procedure-specific analgesia. The treatment opportunity extends across a national livestock base exceeding 536 million animals and poultry population exceeding 851 million, while chronic osteoarthritis, surgical intervention, trauma, and geriatric pet care are expanding the clinical need for repeat pain-management regimens. India's animal-health ecosystem consequently supports both high-volume livestock formulations and higher-value companion-animal therapies.

India Veterinary Analgesics Anti-Inflammatory Market Drivers

Expanding Livestock Healthcare and Companion-Animal Treatment

India's 536.76 million livestock population, including 303.76 million bovines, 193.46 million cattle, 148.88 million goats, and 74.26 million sheep, creates substantial recurring requirements for inflammation, fever, injury, lameness, postoperative pain, and musculoskeletal treatment. Livestock numbers increased 4.6% from the preceding census, while poultry numbers reached 851.81 million after a 16.8% increase, widening the addressable treatment population for veterinary pharmaceuticals.

India Veterinary Analgesics Anti-Inflammatory Market Opportunities

Premium Pet Therapeutics and Improved Veterinary Access

Expansion of veterinary hospitals, specialty pet practices, online consultation, and organized pharmacies creates opportunities for branded NSAIDs, adjunctive therapies, chewables, and chronic-pain protocols. India recorded 9.43 million dogs in the 2019 livestock census in addition to 15.30 million stray dogs, while the wider animal base exceeds 536 million livestock. Greater diagnosis of osteoarthritis and postoperative pain can therefore broaden treatment penetration across both urban companion-animal and rural livestock settings.

India Veterinary Analgesics Anti-Inflammatory Market Segmentation

The industry is segmented by drug class, animal type, route of administration, indication, distribution channel, and end user. Based on supplied numerical data, NSAIDs command approximately 45.1% of drug-class revenue in 2026, while companion animals account for approximately 61.4% of animal-type revenue.

By Drug Class

NSAIDs are the largest drug class, increasing from USD 59.69 million in 2025 to USD 63.80 million in 2026 and USD 108.73 million by 2034 at 6.89% CAGR. Products include carprofen, meloxicam, firocoxib, deracoxib, robenacoxib, ketoprofen, flunixin meglumine, and tolfenamic acid.

NSAIDs are also the fastest-growing reported drug class at 6.89% CAGR. Opioids rise from USD 56.35 million in 2026 to USD 94.89 million in 2034 at 6.73%, while adjunctive analgesics advance from USD 21.33 million to USD 35.17 million at 6.45%.

By Animal Type

Companion animals represent the largest category at USD 86.77 million in 2026, up from USD 81.21 million in 2025, and are forecast at USD 147.43 million by 2034 with 6.85% CAGR. Dogs and cats constitute the principal treatment populations, supplemented by rabbits, ferrets, and other companion species.

Companion animals are additionally the faster-growing reported category at 6.85% CAGR. Livestock animals increase from USD 54.66 million in 2026 to USD 90.67 million by 2034 at 6.53%, encompassing cattle, swine, poultry, sheep and goats, and horses.

By Route of Administration

Oral tablets, chewables, liquids and suspensions compete with injectable, topical/transdermal patches, creams, gels, and other formulations. Numerical revenue or CAGR values for these subsegments were not supplied; therefore, no unsupported segment valuation is assigned. The overall industry nevertheless expands from USD 141.48 million in 2026 to USD 238.79 million by 2034.

By Indication

Applications include postoperative pain, musculoskeletal disorders such as osteoarthritis, equine colic, fever and inflammation, and infectious-disease-associated pain. No indication-level revenue or CAGR figures were supplied. Across all indications, the forecast implies an approximately USD 97.31 million increase between 2026 and 2034.

By Distribution Channel

Veterinary clinics and hospitals, retail pharmacies, online pharmacies, and feed stores/agricultural cooperatives constitute the principal channels. Channel-specific financial values were not provided, preventing defensible allocation of the USD 141.48 million 2026 total or the USD 238.79 million 2034 forecast.

By End User

Veterinarians, pet owners, livestock owners/farmers, and animal-welfare organizations form the primary end-user groups. With companion animals contributing approximately 61.4% of reported animal-type revenue in 2026 and livestock animals approximately 38.6%, prescribing and purchasing requirements differ significantly between urban pet care and production-animal settings.

India Veterinary Analgesics Anti-Inflammatory Market Outlook

India constitutes the geographic scope of the supplied dataset, and no state- or zone-level revenue allocation was provided; therefore, regional financial shares are not fabricated. At the national level, revenue increases from USD 132.53 million in 2025 to USD 141.48 million in 2026 and USD 238.79 million by 2034. The underlying production-animal environment comprises 536.76 million livestock and 851.81 million poultry.

Livestock-related demand is supported by 193.46 million cattle, 109.85 million buffaloes, 148.88 million goats, 74.26 million sheep, and 9.06 million pigs. Companion animals represent approximately 61.4% of supplied 2026 animal-type revenue versus 38.6% for livestock animals, indicating stronger monetization per treated companion animal despite India's much larger production-animal population.

Top players in India Veterinary Analgesics Anti-Inflammatory Market

• Boehringer Ingelheim
• Zoetis
• Elanco Animal Health
• Merck & Co.
• Dechra Pharmaceuticals
• Vetoquinol
• Virbac
• Ceva Santé Animale
• Norbrook Laboratories
• Ashish Life Science
• SeQuent Scientific
• Intas Animal Health
• Hester Biosciences
• Zenex Animal Health
• Vetindia Pharmaceuticals

Prominent global and Indian veterinary-health participants identified across industry sources include Boehringer Ingelheim, Zoetis, Elanco, Merck, Dechra, Vetoquinol, Norbrook, Ceva, Ashish Life Science, SeQuent Scientific, and Vetindia.

• Zoetis

Zoetis is identified among leading veterinary pain-management companies, supported by extensive veterinary pharmaceutical R&D and established relationships with veterinarians. No defensible India-specific percentage company share is available in the supplied dataset or reviewed evidence, so a fabricated share is excluded. The company competes within a national opportunity moving from USD 141.48 million in 2026 to USD 238.79 million in 2034, with companion animals representing the larger supplied animal-type category.

Recent Developments in India Veterinary Analgesics Anti-Inflammatory Market

• 2026: India's Department of Animal Husbandry & Dairying continued implementation of the 21st Livestock Census, strengthening the statistical framework for animal-health planning across livestock and poultry populations.
• 2025: Industry reporting highlighted continued investment by Hester Biosciences in R&D for heat-stable veterinary vaccines suited to India's climatic conditions.

Research Methodology

The assessment uses the supplied 2025, 2026, and 2034 market values as the mandatory quantitative foundation. Segment percentages were calculated directly from supplied totals; for example, USD 63.80 million of USD 141.48 million produces an approximately 45.1% NSAID contribution in 2026. External evidence was restricted to contextual validation of livestock populations, competitive participation, technology developments, and industry events. Where route, indication, channel, end-user, regional, or company-level financial data were not provided, values were not estimated or fabricated. Forecast interpretation consequently preserves the supplied USD 141.48 million 2026 value, USD 238.79 million 2034 endpoint, and 6.69% CAGR as the primary quantitative benchmarks.